Home  |  Site Map  |  Glossary  | Contact
SEPT. 17 QLT Provides Update on Merger with Auxilium Pharmaceuticals, Inc.
   
Sept. 12

QLT Announces Positive Final Results from Phase 1b Retreatment Trial with Oral Synthetic cis-Retinoid (QLT091001) in Subjects with LCA or RP Due to Mutations in RPE65 or LRAT

   
Aug. 7 QLT Announces Adoption of Advance Notice Policy
   
Aug. 5 QLT Announces Second Quarter 2014 Results
   
July 14 QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis due to LRAT or RPE65 Mutations
   
   
Sept. 13

Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT

 
Copyright 2000-2009 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
 
Employee Login
 
'ss